Back to Agenda
The FDA's Clinical Trial Diversity Initiative in the Setting of the Ongoing COVID-19 Pandemic
Session Chair(s)
Wambui Chege, MD, FACP
Physician Policy Advisor, DMPD, OMP, CDER
FDA, United States
FDA’s commitment to Clinical Trial (CT) diversity is integral to the agency’s mission. Recognizing that COVID-19 affects certain populations differently, FDA’s session will explore solutions and stakeholder collaborations in support of CT diversity.
Learning Objective : Recognize how the COVID-19 pandemic underscores the need for clinical trial diversity; Identify ways to increase underrepresented populations in clinical trials in accordance with FDA policy guidance; Evaluate the effectiveness of current FDA policy initiatives aimed at increasing historically underrepresented populations in clinical trials.
Speaker(s)
Panelist
Richardae Araojo, PharmD, MS
FDA, United States
Associate Commissioner for Minority Health, Director, Office of Minority Health
Panelist
John Concato, MD, MPH, MS
FDA, United States
Associate Director for Real-World Evidence Analytics, OMP, CDER
Panelist
Peter Basseches, PhD
Merck & Co., Inc, United States
Distinguished Scientist, Global Regulatory Affairs and Clinical Safety
Panelist
Anu Osinusi, MD, MPH
Gilead Sciences, Inc., United States
Vice President, Hepatitis, Respiratory and Emerging Viruses
Panelist
Richard Knight, MBA
American Association of Kidney Patients , United States
President
Panelist
John Whyte, DrMed, MD, MPH
WebMD, United States
Chief Medical Officer
Have an account?